Your cart is currently empty!
Letall (Letrozole) Tablet
References Cipla (EU) Limited, Electronic Medicines Compendium (EMC), [Revised on Oct 2021], [Accessed on 22th Mar 2023], https://www.medicines.org.uk/emc/files/pil.9957.pdf Novartis Pharmaceuticals Corporation, [Revised on May 2020], [Accessed on 22th Mar 2023], https://www.novartis.us/sites/www.novartis.us/files/Femara.pdf?TB_iframe=true HIGHLIGHTS OF PRESCRIBING INFORMATION. (n.d.). [online] www.accessdata.fda.gov. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020726s027lbl.pdf [Accessed on 22th Mar 2023]. Edward Chu, Cancer Chemotherapy, Lange’s Basic and Clinical Pharmacology, 14th Edition, 2018, 948-976. KD Tripathi, Estrogens, Progestins and Contraceptives, Essentials of Medical Pharmacology, 8th Edition, 2019, 330-353.
Description
Description
This page contains brief details about the drug letrozole, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
The U.S. FDA approved Letrozole as an anticancer medication to treat t early and advanced hormone receptor-positive breast cancer in postmenopausal women on 25th July 1997.
Mechanism of Action of Letrozole
Letrozole is a nonsteroidal compound that inhibits estrogen production by blocking the enzyme aromatase. This medicine reduces the tumor size and stops or slows the progression of the disease, avoiding the reoccurring of early-stage breast cancer and improving the survival rate.
Uses of Letrozole
Letrozole tablet has been developed to treat early and advanced hormone receptor-positive breast cancer in postmenopausal women who have not responded to Tamoxifen therapy. It is also used to support standard treatment for postmenopausal women with early breast cancer.
Letrozole Dosage available
Letrozole is available as a film-coated tablet indicated for oral intake with or without meals. The usual recommended dose is 2.5mg daily, but your physician will choose the dosage and administration frequency incase if you have a liver impairment or any other medical condition.
We can ship to :
News/Updates
References
1. Bristol Myers Squibb, US Food & Drug Administration, [Revised on May 2022] [Accessed on 7th Sep 2022], https://packageinserts.bms.com/pi/pi_revlimid.pdf
2. Anton Wellstein, Giuseppe Giaccone, Michael B. Atkins, and Edward A. Sausville, Pathway-Targeted Therapies: Monoclonal Antibodies, Protein Kinase Inhibitors, and Various Small Molecules, Goodman & Gilman’s Pharmacological Basis of Therapeutics, 13th Edition, 2018, 1203-1236.
